Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

Haematologica. 2018 Jan;103(1):e5-e9. doi: 10.3324/haematol.2017.177600. Epub 2017 Oct 19.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Trials, Phase II as Topic
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • Humans
  • Janus Kinases / metabolism*
  • Molecular Targeted Therapy / adverse effects
  • Molecular Targeted Therapy / methods
  • Myeloproliferative Disorders / diagnosis
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / etiology
  • Myeloproliferative Disorders / metabolism*
  • STAT Transcription Factors / metabolism*
  • Signal Transduction / drug effects*
  • Splenomegaly / drug therapy*
  • Splenomegaly / metabolism
  • Splenomegaly / pathology
  • Treatment Outcome

Substances

  • HSP90 Heat-Shock Proteins
  • STAT Transcription Factors
  • Janus Kinases